Clinical Syndrome Clinical Trial
Official title:
A Randomized Controlled Trial of Oral Ivermectin for Patients With Chikungunya Viral Infection During Urban Outbreak in Southern Thailand
Verified date | February 2024 |
Source | Prince of Songkla University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chikungunya viral infection (CVI) is a mosquito-borne infection, caused by chikungunya virus (CHIKV), an alphavirus, belonging to the family Togaviridae. This infection causes febrile illness associated with high fever, rash, acute deliberating and persistent arthralgia. There is no licensed vaccine or specific treatment for this infection. Ivermectin (IVM), commonly-used antiparasitic, has been demonstrated to inhibit replication of CHIKV.
Status | Completed |
Enrollment | 120 |
Est. completion date | January 26, 2024 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - patients with virologic confirmation of chikungunya infection who had symptoms less than 72 hours prior to visit Exclusion Criteria: - patients with virologic confirmation of chikungunya infection who had symptoms more than 72 hours prior to visit |
Country | Name | City | State |
---|---|---|---|
Thailand | Prince of Songkla University | Hat Yai | Songkhla |
Lead Sponsor | Collaborator |
---|---|
Prince of Songkla University |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Day of fever clearance | 120 participants would be under Body Temperature Assessment - the staff would assess once daily until the fever clearance was below 38C and the measure proportion of patients with fever clearance in each day of assessment until fever clearance at least in 7 days | 1 week | |
Secondary | Day of virologic clearance | 120 participants would be obtained blood examination for virological testing every day until virological clearance at least in 7 days | 1 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04571021 -
Implementation of the Individual Danish Emergency Process Triage
|
N/A | |
Completed |
NCT05060692 -
Changes of NLF in Serum of Long COVID Patients
|
||
Recruiting |
NCT06102655 -
Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency Based on Metabolomics
|
Early Phase 1 | |
Recruiting |
NCT06109337 -
Immunoprofilling of Peripheral Blood Mononuclear Cells in Children With Attention Deficit/Hyperactivity Disorder
|